DHJJ Financial Advisors Ltd. Grows Position in Bristol Myers Squibb Company $BMY

DHJJ Financial Advisors Ltd. grew its stake in Bristol Myers Squibb Company (NYSE:BMY) by 51.9% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 781 shares of the biopharmaceutical company’s stock after purchasing an additional 267 shares during the period. DHJJ Financial Advisors Ltd.’s holdings in Bristol Myers Squibb were worth $36,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of the stock. Brighton Jones LLC lifted its position in shares of Bristol Myers Squibb by 33.4% during the 4th quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock valued at $1,116,000 after buying an additional 4,935 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. lifted its position in shares of Bristol Myers Squibb by 21.4% during the 1st quarter. Thurston Springer Miller Herd & Titak Inc. now owns 7,062 shares of the biopharmaceutical company’s stock valued at $431,000 after buying an additional 1,246 shares in the last quarter. Thrive Wealth Management LLC lifted its position in shares of Bristol Myers Squibb by 4.1% during the 1st quarter. Thrive Wealth Management LLC now owns 5,875 shares of the biopharmaceutical company’s stock valued at $358,000 after buying an additional 232 shares in the last quarter. Charles Schwab Trust Co purchased a new position in shares of Bristol Myers Squibb during the 1st quarter valued at approximately $285,000. Finally, Vest Financial LLC lifted its position in shares of Bristol Myers Squibb by 73.5% during the 1st quarter. Vest Financial LLC now owns 16,912 shares of the biopharmaceutical company’s stock valued at $1,031,000 after buying an additional 7,166 shares in the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Stock Down 0.7%

Shares of BMY opened at $45.39 on Friday. Bristol Myers Squibb Company has a 52-week low of $42.96 and a 52-week high of $63.33. The company has a market capitalization of $92.38 billion, a PE ratio of 18.30, a price-to-earnings-growth ratio of 2.34 and a beta of 0.33. The stock has a fifty day simple moving average of $46.36 and a two-hundred day simple moving average of $48.65. The company has a quick ratio of 1.11, a current ratio of 1.21 and a debt-to-equity ratio of 2.54.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.07 by $0.39. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The business had revenue of $12.27 billion during the quarter, compared to the consensus estimate of $11.32 billion. During the same period last year, the company earned $2.07 EPS. The company’s revenue for the quarter was up .6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. As a group, equities analysts forecast that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, November 3rd. Shareholders of record on Friday, October 3rd will be paid a $0.62 dividend. The ex-dividend date of this dividend is Friday, October 3rd. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.5%. Bristol Myers Squibb’s dividend payout ratio (DPR) is 100.00%.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. Morgan Stanley reiterated a “hold” rating on shares of Bristol Myers Squibb in a research report on Thursday, July 31st. Daiwa Capital Markets lowered Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 price objective on the stock. in a report on Tuesday, August 5th. Citigroup decreased their price objective on Bristol Myers Squibb from $51.00 to $47.00 and set a “neutral” rating on the stock in a report on Friday, August 1st. Wall Street Zen lowered Bristol Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Friday, June 6th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Bristol Myers Squibb in a report on Saturday, September 27th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, sixteen have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Bristol Myers Squibb has an average rating of “Hold” and a consensus price target of $56.38.

Insider Activity

In other Bristol Myers Squibb news, EVP David V. Elkins sold 56,000 shares of the firm’s stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total value of $2,650,480.00. Following the completion of the sale, the executive vice president directly owned 167,379 shares of the company’s stock, valued at $7,922,048.07. This trade represents a 25.07% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.09% of the stock is owned by company insiders.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.